Landscape Capital Management L.L.C. Grows Stock Position in Edwards Lifesciences Corp (NYSE:EW)

Share on StockTwits

Landscape Capital Management L.L.C. raised its holdings in Edwards Lifesciences Corp (NYSE:EW) by 365.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,517 shares of the medical research company’s stock after buying an additional 16,893 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Edwards Lifesciences were worth $3,975,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Mercer Global Advisors Inc. ADV purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $843,000. Wendell David Associates Inc. raised its stake in shares of Edwards Lifesciences by 1.7% in the second quarter. Wendell David Associates Inc. now owns 12,100 shares of the medical research company’s stock worth $2,235,000 after purchasing an additional 207 shares during the last quarter. Wetherby Asset Management Inc. raised its stake in shares of Edwards Lifesciences by 11.5% in the first quarter. Wetherby Asset Management Inc. now owns 3,273 shares of the medical research company’s stock worth $626,000 after purchasing an additional 337 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in shares of Edwards Lifesciences by 7.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,553 shares of the medical research company’s stock worth $3,741,000 after purchasing an additional 1,403 shares during the last quarter. Finally, Ballentine Partners LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $243,000. Institutional investors own 82.43% of the company’s stock.

In related news, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $184.27, for a total transaction of $4,210,569.50. Following the transaction, the chief executive officer now owns 95,770 shares in the company, valued at $17,647,537.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Schack Wesley W. Von sold 3,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $217.27, for a total value of $651,810.00. Following the transaction, the director now owns 1,737 shares in the company, valued at approximately $377,397.99. The disclosure for this sale can be found here. In the last quarter, insiders have sold 142,948 shares of company stock worth $27,936,332. 1.63% of the stock is currently owned by company insiders.

Several research analysts have recently issued reports on EW shares. Canaccord Genuity raised their price objective on Edwards Lifesciences from $215.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Morgan Stanley raised their price objective on Edwards Lifesciences from $210.00 to $228.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 24th. Barclays lifted their price target on Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research report on Wednesday, July 24th. Bank of America reiterated a “buy” rating and set a $225.00 price target (up from $215.00) on shares of Edwards Lifesciences in a research report on Wednesday, July 24th. Finally, Jefferies Financial Group lifted their price target on Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $204.74.

Shares of NYSE:EW traded up $1.64 during trading on Thursday, reaching $215.15. The stock had a trading volume of 54,630 shares, compared to its average volume of 1,186,828. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average of $200.64. The company has a market cap of $44.90 billion, a PE ratio of 45.79, a PEG ratio of 2.72 and a beta of 0.87. Edwards Lifesciences Corp has a 1-year low of $134.53 and a 1-year high of $219.71.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.33 by $0.05. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. The business’s revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.24 earnings per share. Research analysts expect that Edwards Lifesciences Corp will post 5.34 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Hold Rating

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.